Navigation Links
Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Date:4/1/2009

RIDGEFIELD, Conn., April 1 /PRNewswire/ -- On April 1, 2009, Xmark Opportunity Partners, LLC, the sole member of the investment manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the following letter to the Board of Directors of Icagen, Inc. (Nasdaq: ICGN).

                            XMARK OPPORTUNITY PARTNERS, LLC
                                    90 Grove Street
                                       Suite 201
                             Ridgefield, Connecticut 06877

                                                               April 1, 2009
    VIA E-MAIL
    Board of Directors
    Icagen, Inc.
    4222 Emperor Boulevard
    Suite 350
    Durham, NC  27703

Lady and Gentlemen:

There are four words that no one ever wants to say: I told you so. For almost a year, we have been telling you to pursue strategic alternatives; we told you so when Icagen had a higher stock price, more cash and a cleaner profile for its compounds. We have been telling you so as the markets have fallen further and further, and as the company's cash on hand has fallen concomitantly.

We believe that the management team and the Board of Directors have failed miserably and repeatedly. In an era where stalwart companies such as General Motors, Citigroup and Lehman Brothers have had high-level management turnover due to the failure of their respective management teams, in our opinion, there is absolutely no reason why Icagen should not follow suit.

Accordingly, we call on the Board to immediately (a) initiate a public search for a replacement Chief Executive Officer, (b) hire an investment banker to evaluate and pursue strategic alternatives so that the company's shareholders are not left holding a "zero" in the near to mid-term, and (c) remove the recently-adopted poison p
'/>"/>

SOURCE Xmark Opportunity Partners, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
2. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
3. CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement
4. Sinovac Requests Extension for Annual Shareholders Meeting
5. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
6. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
7. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
8. Covance Decides to Pursue Its Original Preclinical Strategy in China
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)... , The concept of confinement is one of the ce...mple is that of quarks which bind together to form...elmholtz-Zentrum Berlin together with an internati...an experimental realization and a proof of confine...tem. , The concept of confinement states that in...
(Date:11/26/2009)...on of ultrasmall transistors and more powerful com...cting nanowires are closer to reality after a key ... and the University of California at Los Angeles. ...owires with layers of different materials that are...ritical requirement for making efficient transisto...
(Date:11/25/2009)...e/ - Cytochroma today announced the appointment of...oldt will replace Mr. Ulrik Spork as the Novo A/S ...of Board members remains unchanged at six members.... to the board and look forward to benefiting from ...s to make progress in becoming a leading CKD-focus...
(Date:11/24/2009)...e-FirstCall/ -- IES (Nasdaq: IESC ), a leading na...ystems and services for the commercial, industrial... commercial business group has been awarded a cont...rical systems for the Level 4 bio-safety lab (BSL-...esearch Institute of Infectious Diseases (USAMRIID...
Breaking Biology Technology:Spinons -- confined like quarks 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...ction July 27, 2008 Completes Enrollment for VEC... Md., Feb. 14 Vanda Pharmaceuticals,Inc. (Nasdaq:...he development,and commercialization of clinical-s... disorders, today announced financial and operatio... ended December 31, 2007., Vanda reported researc...
...nch; Positioned for Expanded Growth in ...th Quarter and 2007 Financial Highlights:, * Soli...illion in Q4 2007, compared to net product sale...s was $12.3 million, or $0.33 per share, compared ...er share, in Q3 2007., * Q4 non-GAAP net loss was...
...nced,today that the Chicago Athenaeum Museum of Ar...GN(TM) Award for the new SoloSTAR(R) disposable,in...e 2 diabetes., "LANTUS(R) SoloSTAR(R) and APIDRA(...intensive development, have been designed in dialo... high standards of the industry,",said Paul Jansen...
Other Biology Technology:Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 2Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 3Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 4Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 5
(Date:11/30/2009)...registration rates and register online now for the.../www.iofwco-ecceo10.org/ , WHAT: IOF WCO-ECCEO...orosis Foundation (IOF) and the European Society f...nd Osteoarthritis (ESCEO). More than 5,000 partici.... The exciting scientific programme includes 12 pl...
(Date:11/30/2009)...eeing your extended family over the holidays was s...n the December 2009 print issue of the Journal of...ows that you might be right. Here,s the good news:...y new treatments that help keep autoimmune disease... That,s because researchers from the University of...
(Date:11/30/2009)..., Nov. 30 Neurotechnology ( http:/...cision biometric identification technologies, has ...oduct line: VeriLook 4.0 Software Development Ki....1 SDK for large-scale multi-biometric and automat...nded capabilities in VeriLook 4.0 provide enhanced...
Breaking Biology News(10 mins):Seeing family for the holidays? Scientists discover how the stress might kill you 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 2Five Questions About Protopic 28tacrolimus 29 Ointment 13332 3Five Questions About Protopic 28tacrolimus 29 Ointment 13332 4Synthetic biology opportunities and risks 53488 1Synthetic biology opportunities and risks 53488 2Synthetic biology opportunities and risks 53488 3
...lcome Fund has announced the recipients of the 200...Disease awards. , The Investigators in the Pathog...0 during a five-year period to encourage aggressiv...athogenesis. BWF launched the program in 2002 and... $30 million in the careers of investigators who a...
... has developed a new water treatment that could he.... , David Hand, a professor of civil and environm...simple way to treat ballast water in vessels rangi... designed to kill the virus that causes viral hemo...hat has been attacking fish populations in the low...
...the 2008 Environmental Scientists of the Year by T...rother, biologist Jules Blais, is the other winner...tigious in the environmental sciences. The prize r...ic work to Canadian society. , Smol is series ed...aleoenvironmental Research and has also edited man...
Other Biology News:BWF awards $7 million to infectious disease investigators 2New ballast treatment could protect Great Lakes fish 2
EZ-Retriever System from BioGenex
...00 drug discovery system miniaturizes, integrates ...ing LabChip technology, the LabChip 3000 performs ... fashion. LabChip assays are separations-based, so... in homogenous, well-based assays. No other screen...
Fluorogenic Chip, 4-Sipper from Caliper Life Sciences
...ystem, 100-120 and 220-240 V, is a microfluidics-b...ed electrophoresis, including some data analysis, ...or protein analysis (it does not include the vorte...ncludes the electrophoresis station, priming stati...
Biology Products: